Purdue Pharma
Purdue Pharma and its subsidiaries are physician-founded and physician-led companies that develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers.
About - Purdue Pharma
Purdue Pharma and its subsidiaries develop, manufacture and market medications to meet the evolving needs of healthcare professionals, patients and caregivers. Purdue’s plan of reorganization will deliver billions in value to communities across the country to fund programs specifically for abatement of the opioid crisis.
Products - Purdue Pharma
Purdue and its subsidiaries are pioneers in medical science with a patient-first approach in developing prescription and non-prescription medications. We focus on balancing innovative science with clinically effective, compassionate care.
News & Media - Purdue Pharma
Oct 28, 2024 · STAMFORD, Conn., August 7, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the Zurnai™ (nalmefene injection) Auto-Injector. Zurnai (zur nye) is a single-dose…
Restructure - Purdue Pharma
Purdue continues to work tirelessly with creditors to reach a new settlement that delivers billions of dollars of value for opioid abatement and allows the Company to emerge from bankruptcy as a company with a public-minded mission.
Medicines From Purdue - Purdue Pharma
Purdue is a pioneer in healthcare, with a patient-first approach in developing medicines. We combine medical science with compassionate care in every phase of drug research and manufacturing.
Study Examining Use of Nalmefene HCI Injection for Opioid …
STAMFORD, Conn., Sept. 30, 2024 – Purdue Pharma has completed the first phase of a study examining the use of nalmefene hydrochloride (HCI) injection in real-world emergency department (ED) settings. Researchers are now conducting data …
FDA Accepts Filing of New Drug Application for ... - Purdue Pharma
STAMFORD, Conn., April 08, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*. If the auto-injector is approved, it would be the second nalmefene-containing medicine developed by Purdue to ...
Healthcare Professionals - Purdue Pharma
Purdue Pharma develops and provides prescription medicines that meet the evolving needs of healthcare professionals, patients, and caregivers. For decades, we have developed medications that manage pain.
What We Offer You - Purdue Pharma
At Purdue Pharma and its subsidiaries, we foster a supportive environment that develops colleagues, rewards performance, and incents long-term success. We provide competitive compensation, comprehensive benefits, and opportunities for advancement within a …